300 related articles for article (PubMed ID: 35729828)
1. IL-33 in autoimmunity; possible therapeutic target.
Yuan C
Int Immunopharmacol; 2022 Jul; 108():108887. PubMed ID: 35729828
[TBL] [Abstract][Full Text] [Related]
2. IL-33/ST2 axis in autoimmune disease.
Shakerian L; Kolahdooz H; Garousi M; Keyvani V; Kamal Kheder R; Abdulsattar Faraj T; Yazdanpanah E; Esmaeili SA
Cytokine; 2022 Oct; 158():156015. PubMed ID: 36041312
[TBL] [Abstract][Full Text] [Related]
3. IL-33/ST2 axis in inflammation and immunopathology.
Milovanovic M; Volarevic V; Radosavljevic G; Jovanovic I; Pejnovic N; Arsenijevic N; Lukic ML
Immunol Res; 2012 Apr; 52(1-2):89-99. PubMed ID: 22392053
[TBL] [Abstract][Full Text] [Related]
4. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
5. The Role of the IL-33/ST2 Immune Pathway in Autoimmunity: New Insights and Perspectives.
Ramezani F; Babaie F; Aslani S; Hemmatzadeh M; Mohammadi FS; Gowhari-Shabgah A; Jadidi-Niaragh F; Ezzatifar F; Mohammadi H
Immunol Invest; 2022 May; 51(4):1060-1086. PubMed ID: 33522348
[TBL] [Abstract][Full Text] [Related]
6. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
7. Osteopontin in autoimmune disorders: current knowledge and future perspective.
Xu C; Wu Y; Liu N
Inflammopharmacology; 2022 Apr; 30(2):385-396. PubMed ID: 35235108
[TBL] [Abstract][Full Text] [Related]
8. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases.
Antonelli A; Ferrari SM; Giuggioli D; Ferrannini E; Ferri C; Fallahi P
Autoimmun Rev; 2014 Mar; 13(3):272-80. PubMed ID: 24189283
[TBL] [Abstract][Full Text] [Related]
9. IL-33: a potential therapeutic target in autoimmune diseases.
Wang S; Ding L; Liu SS; Wang C; Leng RX; Chen GM; Fan YG; Pan HF; Ye DQ
J Investig Med; 2012 Dec; 60(8):1151-6. PubMed ID: 23076162
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-13: A promising therapeutic target for autoimmune disease.
Mao YM; Zhao CN; Leng J; Leng RX; Ye DQ; Zheng SG; Pan HF
Cytokine Growth Factor Rev; 2019 Feb; 45():9-23. PubMed ID: 30581068
[TBL] [Abstract][Full Text] [Related]
11. Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10.
Ireland SJ; Monson NL; Davis LS
Cytokine; 2015 Jun; 73(2):236-44. PubMed ID: 25794663
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases.
Chen WY; Tsai TH; Yang JL; Li LC
Cell Physiol Biochem; 2018; 49(1):349-358. PubMed ID: 30138941
[TBL] [Abstract][Full Text] [Related]
13. AhR-ROR-γt complex is a therapeutic target for MAP4K3/GLK
Chuang HC; Chen YM; Chen MH; Hung WT; Yang HY; Tseng YH; Tan TH
FASEB J; 2019 Oct; 33(10):11469-11480. PubMed ID: 31318609
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of IL-35 in inflammatory autoimmune diseases.
Su LC; Liu XY; Huang AF; Xu WD
Autoimmun Rev; 2018 Jul; 17(7):665-673. PubMed ID: 29729445
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance and immunobiology of IL-21 in autoimmunity.
Long D; Chen Y; Wu H; Zhao M; Lu Q
J Autoimmun; 2019 May; 99():1-14. PubMed ID: 30773373
[TBL] [Abstract][Full Text] [Related]
16. Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene modulation: A comprehensive review.
Lee KH; Ahn BS; Cha D; Jang WW; Choi E; Park S; Park JH; Oh J; Jung DE; Park H; Park JH; Suh Y; Jin D; Lee S; Jang YH; Yoon T; Park MK; Seong Y; Pyo J; Yang S; Kwon Y; Jung H; Lim CK; Hong JB; Park Y; Choi E; Shin JI; Kronbichler A
Autoimmun Rev; 2020 Mar; 19(3):102469. PubMed ID: 31918027
[TBL] [Abstract][Full Text] [Related]
17. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity.
Kunz M; Ibrahim SM
Mediators Inflamm; 2009; 2009():979258. PubMed ID: 19884985
[TBL] [Abstract][Full Text] [Related]
18. Natural products action on pathogenic cues in autoimmunity: Efficacy in systemic lupus erythematosus and rheumatoid arthritis as compared to classical treatments.
Cao F; Cheng MH; Hu LQ; Shen HH; Tao JH; Li XM; Pan HF; Gao J
Pharmacol Res; 2020 Oct; 160():105054. PubMed ID: 32645358
[TBL] [Abstract][Full Text] [Related]
19. The role of the IL-33/ST2 axis in autoimmune disorders: Friend or foe?
Liu X; Xiao Y; Pan Y; Li H; Zheng SG; Su W
Cytokine Growth Factor Rev; 2019 Dec; 50():60-74. PubMed ID: 31085085
[TBL] [Abstract][Full Text] [Related]
20. Involvement of IL-33 in the Pathophysiology of Systemic Lupus Erythematosus: Review.
Sarrand J; Soyfoo M
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
